

Technology Platform:

Anti-Thrombotic Oral Therapies

Embotricin™

MOA: endothelial glycocalyx repair, inflammation and oxidation

Multiplex Diagnostic Tools

GlycoCardia™

4-marker kit to monitor drug efficacy

Glycalyx Detritus Fingerprint™

7-marker kit for disease identification, staging & characterization

Intellectual Properties:

(Issued) Biomarkers of Vascular Disease

(Issued) Methods and Compositions for Reversing Disruption of the Glycocalyx, Inflammation and Oxidative Damage

(Pending) Drug Treatment & Biomarker Panel Targeted to Diseases Due to Multifactorial Ontology of Glycocalyx Disruption

(Draft) Animal Model for CVD & Inflammation PCT and additional filings in process

Multiple trademarks awarded and in process

Clinical Targets:

Embotricin™ FDA IND indications:

Pulmonary Hypertension

Dialysis Fistula (IND optional)

Embotricin™ Proof of Principle/non-US:

Heart Failure

Coronary Artery Disease

GlycoCardia™ multiplex

Surrogate markers to measure drug effect

Pre-clinical Providers:

DSK – GLP compound manufacturing

Wayne State Bio – ELISA studies

Henry Ford Hospital – translational studies

Camargo Research – CRO selection, oversight

Camargo Regulatory – FDA, regulatory

Theraquila – in vitro, in vivo toxicology

Utah State – pollutant & optimization

Clinical Network Svcs – GAP analysis/AUS

Clinical Providers:

Cambrex – GMP manufacturing & formulation

Transhit-Bio – clinical bio-samples sourcing

Arbor Assays – 7-disease ELISA pilots

M. Perera, PhD – Analysis & Algorithms

Dr. Bonnie Weiner – clinical strategy & PI

TBD – clinical investigator (US and AUS)

Legal and Advisory:

Weaver Austin Villeneuve & Sampson LLP

Intellectual Properties

Bodman PLC

Corporate filings, offering documentation

Varnum LLP

Trademarks, Publishing

Garrett & Bachand PC

General counsel & advisory

Croskey Lanni PC

Corporate Accounting

ABA Consulting

Corporate Advisory (AUS)

Cardiovascular Disease (CVD) is the world's leading chronic disease killer impacting more than one-third of the world's population. Among the top 150 developing nations worldwide, CVD is the largest health risk and cost. In the 1940's, the discovery of penicillin spawned the antibiotic industry and the treatment paradigm of one antibiotic to one microbial infection which effectively eliminated the targeted microbe and cured the corresponding disease. This one-drug-one-disease paradigm was carried over to the current treatment of other diseases, however mono-therapies cannot address the multifactorial etiology of chronic diseases.



Arterez, Inc. is a Michigan biosciences group focused on the discovery and development of therapeutics and diagnostics against chronic diseases. Our platform involves proprietary combo therapies and multi-marker diagnostics to address the multifactorial nature of chronic disease which starts with the disruption of the cell's protective shield, the glycocalyx, triggered by a number of environmental and extraneous factors leading to oxidative damage and inflammatory response we've identified collectively as the upstream causes. If this vicious cycle and sequela of damage continues, it manifests into various downstream symptoms which are what are being treated with current monotherapies. Needless to say, treating symptoms of disease downstream is precisely why symptom-targeted drugs cannot cure or prevent disease and are at best palliative.

Initially, we chose cardiovascular disease (CVD) for proof-of-principle of our combo paradigm. Embotricin™ (a triple component oral drug) is our lead therapeutic, which proved curative and preventive of arterial plaque in preclinical studies. The effective dose in mice is 3mg/kg with no-observed-adverse-effect-level (NOAEL) at 1,000 mg/kg further confirmed by rat in vivo and histopathology indicating Embotricin™ to be non-toxic with a wide therapeutic window. Preventive and curative treatment effect was confirmed by 4 biomarkers identified from shed glycocalyx detritus clinically correlated to arterial plaques we have since established and patented as a surrogate marker kit to monitor treatment effect, GlycoCardia™ in addition to histopathology and magnetic resonance imaging (MRI) to confirm results.

Glycocalyx disruption generates debris (detritus), which is quantitated by antibody levels; the levels of debris shed to the blood stream is unique to every disease, which is the foundation of GlycoCardia™ and Arterez' Glycalyx Detritus Fingerprint™ (GDF) technology, another proprietary core technology involving the attachment of 7 antibody-analyte complex to color-coded microbeads with fluorescent reporter dye labels; 10X more sensitive and faster (3-hr) than ELISA (60-hr turnaround). Current diagnostics involve one biomarker per disease, which is neither dependable nor accurate. The multi-component GDF offers pattern recognition to provide an accurate fingerprinting system for disease.

Technology Brief

- Dr. Tunac developed and synthesized 9 active compounds leading to Arterez' first abbreviated factorial 3-drug combo Embotricin™ as well as a 4-panel companion diagnostic tool to monitor endothelial glycocalyx health, GlycoCardia™, and finally the Glycocalyx Detritus Fingerprint™, a 7-panel universal diagnostic tool for chronic disease. These are Arterez' first drug and diagnostics platform technologies in our development pipeline.
- Embotricin™ proved to prevent plaque formation and/or restored the integrity of the endothelial glycocalyx as evidenced by the reduction in glycocalyx detritus shed in the bloodstream measured by individual biomarkers that make up the diagnostic panel, GlycoCardia™.
- The effective dose in mice is 3mg/kg with no-observed-adverse-effect-level (NOAEL) up to 1,000 mg/kg in mice and 800mg/kg in rats confirmed by histopathology indicating Embotricin™ is non-toxic.
- GlycoCardia™ utilizes 4 detritus biomarkers including heparan sulfate (HS), Hyaluronan synthase-1 (HAS-), syndecan-1 (SDC-1), and plasminogen activator inhibitor-1 (PAI-1). It is being developed as a companion diagnostic for plaque formation/regression to monitor Embotricin™ efficacy and will be presented as a surrogate end-point to the FDA.
- The Glycocalyx Detritus Fingerprint™ (GDF) consists of the 4 GlycoCardia™ components plus 3 additional biomarkers, including Gamma (γ) fibrinogen (FGG), Growth differentiation factor 15 (GDF-15) and Pregnancy associated plasma protein (PAPP-A). The GDF 7-marker panel is being developed as a universal diagnostic tool for chronic diseases, equivalent to the DNA Fingerprint in forensics.
- Licensing and/or co-development opportunities will be pursued for the diagnostic platform in 2022.
- First in-human 'proof of principle' POC studies against hypertension, heart failure and coronary artery disease are expected to begin 2023 and will run concurrently.
- Independent net present day intellectual property valuations include \$105mm for our therapy vs 3 targeted indications and \$471mm for our IP portfolio over-all.



Dr. Tunac and the Arterez' team are honored to accept the invitation to present our technology innovations at the 2022 World Heart Conference in Singapore

Capital Raise

Arterez is raising a \$2.5 million dollar bridge open to accredited investors. A total of \$10 million will be required to complete all pre-clinical work over 19 months. \$15 million to complete 3 concurrent first in-human efficacy studies against hypertension, heart failure and coronary artery disease.

Exit strategy involves diagnostic licensing (12-18 mos.) and licensing and/or acquisition of Embotricin against one or more indications pre-FDA NDA (32-36 mos.) and public offering to enable further pipeline development.

About Dr. Joe Tunac, Inventor, Founder, President & Chairman

Medical scientist specializing in the discovery and development of drugs. He studies the biochemistry and physiology of the human body and designs drugs to target the dysfunctional mechanisms. He obtained his undergraduate degree from the University of the Philippines then graduate studies at South Dakota State, Penn State and a doctorate degree from Rutgers, where he studied at the Waksman Institute, the world center for antibiotics.



Merck hired Dr. Tunac as a senior scientist where he was instrumental in the discovery and development of multi-billion dollar drugs, moved to Park-Davis where he continued drug development and commercialization success and then repeated that again as an entrepreneur. He has more than 40 yrs of experience, 30+ patents and patents pending and more than 35 scientific publications. He lives in Oxford, MI.

Due-diligence Information

NON-CONFIDENTIAL DATA-ROOM:

<https://www.dropbox.com/sh/y70B4o1q7p09m/AA4h0NH1vHfGjaH8RlcvRV6a?dl=0>

PUBLISHED WORKS:

https://www.dropbox.com/sh/d5f88z2o1ok8ur/AAAGb1p45669D_natLqN2aERa?dl=0

INTELLECTUAL PROPERTIES:

<https://www.dropbox.com/sh/v56v8qutth1eul/AAAgj-N2FH1K27MwzH1ajV4ms?dl=0>

ACCREDITED INVESTOR DOCUMENTS:

<https://www.dropbox.com/sh/d0md3v7m33edms/AA8V1ak1QZLzPp14Qub8g9e7d?dl=0>

For more information, please contact
Mike Brennan, mike@arterez.com